HOLLISTON, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2023.
Jim Green, Chairman and CEO said, “We are encouraged by the continuation of a strong start to the fiscal year, with growth from new products and our improved portfolio largely offsetting the revenue from discontinued low margin products that we obsoleted last year.”
Green continued, “New products launched in 2022 demonstrate our ability to leverage our recognized technical leadership in academic research and discovery into industrial applications for CRO, pharma and biotech customers, as shown by our initial success in bio-production and in high-capacity behavioral systems. In addition, in the first half of 2023, we began shipping our innovative second-generation MEA (multi electrode array) systems designed for testing at the cell and developing organoid level.”
| Financial Results Summary | |||||||||||||||||||||||||||
| ($ in millions except per share data) | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 | |||||||||||||||||||||||
| Revenues | $ | 28.8 | $ | 29.2 | $ | 58.7 | $ | 58.0 | |||||||||||||||||||
| Gross Margin | 58.0 | % | 57.0 | % | 59.6 | % | 56.6 | % | |||||||||||||||||||
| Operating Income (GAAP) | $ | 0.8 | $ | 4.0 | $ | 2.5 | $ | (2.7 | ) | ||||||||||||||||||
| Adjusted Operating Income | $ | 3.6 | $ | 3.1 | $ | 8.0 | $ | 5.4 | |||||||||||||||||||
| Net (Loss) Income (GAAP) | $ | (1.0 | ) | $ | 2.4 | $ | (0.4 | ) | $ | (4.4 | ) | ||||||||||||||||
| Diluted (Loss) Earnings Per Share (GAAP) | $ | (0.02 | ) | $ | 0.06 | $ | (0.01 | ) | $ | (0.11 | ) | ||||||||||||||||
| Diluted Adjusted Earnings Per Share | $ | 0.04 | $ | 0.05 | $ | 0.09 | $ | 0.08 | |||||||||||||||||||
| Adjusted EBITDA | $ | 3.9 | $ | 3.4 | $ | 8.7 | $ | 6.1 | |||||||||||||||||||
| Adjusted EBITDA Margin | 13.6 | % | 11.6 | % | 14.7 | % | 10.5 | % | |||||||||||||||||||
| Cash Flow provided by (used in) Operations | $ | 3.6 | $ | (0.2 | ) | $ | 5.4 | $ | (2.2 | ) | |||||||||||||||||
| Net Debt* | $ | 37.8 | $ | 45.2 | $ | 37.8 | $ | 45.2 | |||||||||||||||||||
* Debt outstanding plus unamortized deferred financing costs, less cash and cash equivalents as of period end.
Second Quarter 2023 Highlights
For the second quarter of fiscal 2023, the Company reported revenues of $28.8 million, compared to $29.2 million in the second quarter of fiscal 2022. Second quarter revenues include a net reduction of $1.6 million from discontinued products compared to the second quarter of last year. Gross margin for the three months ended June 30, 2023 was 58.0% compared with 57.0% in the comparable quarter of the prior year.
Operating income for the second quarter of fiscal 2023 was $0.8 million, compared to $4.0 million in the same prior year quarter, which included a favorable reversal of litigation reserves of $4.9 million. Adjusted operating income for the second quarter of 2023 was $3.6 million compared to $3.1 million in the prior year period.
Net loss for the second quarter of 2023 was ($1.0) million, including a $1.6 million mark to market reduction of marketable securities, compared to net income of $2.4 million in Q2 2022 which included the aforementioned reversal. Adjusted EBITDA for the second quarter of 2023 was $3.9 million, compared to adjusted EBITDA of $3.4 million in Q2 2022.
Cash provided by operations for the second quarter of 2023 was $3.6 million and net debt was reduced by $3.2 million.
First Half 2023 Highlights
For the six months ended June 30, 2023, revenues were $58.7 million, compared to $58.0 million in the same period a year ago. First half 2023 revenues include a net reduction of $2.8 million from discontinued products compared to the first half of last year. Gross margin for the six months ended June 30, 2023 was 59.6% compared with 56.6% in the comparable period of the prior year.
Operating income for the first half of 2023 was $2.5 million, compared to an operating loss of ($2.7) million in the first half of 2022, which included a litigation reserve of $0.3 million. Adjusted operating income for the first six months of 2023 was $8.0 million compared to $5.4 million in the prior year period.
Net loss for the first half of 2023 was ($0.4) million, including a $1.6 million mark to market reduction of marketable securities, compared to a net loss of ($4.4) million for the comparable period of 2022, including the aforementioned reserve. Adjusted EBITDA for the six months ended June 30, 2023 was $8.7 million, compared to adjusted EBITDA of $6.1 million for the comparable period of 2022.
Cash provided by operations was $5.4 million and net debt was reduced by $5.4 million in the first half of 2023.
2023 Guidance
We expect revenues of approximately $116 million to $120 million for the full year 2023. This expected growth anticipates an approximate 4 percentage point headwind from discontinued products. For the year 2023, we expect gross margins of approximately 60% and adjusted EBITDA margins in the 15% to 17% range. We also remain on the path to reduce our net leverage ratio to approximately 2X by the end of this year.
This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Net leverage ratio is defined under our credit agreement as our net debt divided by our trailing twelve months adjusted EBITDA.
Webcast and Conference Call Details
In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins.
Analysts who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who want to join the audio-only webcast should go to our events and presentations on the investor website here.
Use of Non-GAAP Financial Information
In this press release, we have included non-GAAP financial information, including adjusted operating income (loss), adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings (loss) per share and net leverage ratio. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, litigation settlement, restructuring and other costs, unrealized gain/loss on equity securities and income taxes. They also exclude the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance. Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.
With respect to forward-looking measures, we provide an outlook for adjusted EBITDA margin and net leverage ratio. Many of the items that we exclude from these forward-looking measure calculations are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.
The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Company’s market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
Harvard Bioscience, Inc.
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
(508) 893-3120
| HARVARD BIOSCIENCE, INC. | ||||||||||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||||||||||
| (unaudited, in thousands, except per share data) | ||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||
| June 30, 2023 | June 30, 2022 | June 30, 2023 | June 30, 2022 | |||||||||||||||||||||
| Revenues | $ | 28,759 | $ | 29,208 | $ | 58,734 | $ | 57,986 | ||||||||||||||||
| Cost of revenues | 12,086 | 12,571 | 23,715 | 25,172 | ||||||||||||||||||||
| Gross profit | 16,673 | 16,637 | 35,019 | 32,814 | ||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Sales and marketing expenses | 6,178 | 6,587 | 12,156 | 13,274 | ||||||||||||||||||||
| General and administrative expenses | 5,353 | 5,981 | 11,687 | 12,306 | ||||||||||||||||||||
| Research and development expenses | 2,957 | 3,497 | 5,854 | 6,717 | ||||||||||||||||||||
| Amortization of intangible assets | 1,389 | 1,454 | 2,777 | 2,920 | ||||||||||||||||||||
| Litigation settlement | - | (4,880 | ) | - | 311 | |||||||||||||||||||
| Total operating expenses | 15,877 | 12,639 | 32,474 | 35,528 | ||||||||||||||||||||
| Operating income (loss) | 796 | 3,998 | 2,545 | (2,714 | ) | |||||||||||||||||||
| Other (expense) income: | ||||||||||||||||||||||||
| Unrealized loss on equity securities | (1,581 | ) | - | (1,581 | ) | - | ||||||||||||||||||
| Interest expense | (941 | ) | (515 | ) | (1,915 | ) | (899 | ) | ||||||||||||||||
| Other (expense) income, net | (372 | ) | (62 | ) | 60 | 16 | ||||||||||||||||||
| Total other expense | (2,894 | ) | (577 | ) | (3,436 | ) | (883 | ) | ||||||||||||||||
| (Loss) income before income taxes | (2,098 | ) | 3,421 | (891 | ) | (3,597 | ) | |||||||||||||||||
| Income tax (benefit) expense | (1,118 | ) | 986 | (533 | ) | 848 | ||||||||||||||||||
| Net (loss) income | $ | (980 | ) | $ | 2,435 | $ | (358 | ) | $ | (4,445 | ) | |||||||||||||
| (Loss) income per common share: | ||||||||||||||||||||||||
| Basic | $ | (0.02 | ) | $ | 0.06 | $ | (0.01 | ) | $ | (0.11 | ) | |||||||||||||
| Diluted | $ | (0.02 | ) | $ | 0.06 | $ | (0.01 | ) | $ | (0.11 | ) | |||||||||||||
| Weighted-average common shares: | ||||||||||||||||||||||||
| Basic | 42,354 | 41,304 | 42,204 | 41,256 | ||||||||||||||||||||
| Diluted | 42,354 | 42,560 | 42,204 | 41,256 | ||||||||||||||||||||
| HARVARD BIOSCIENCE, INC. | ||||||||||
| Condensed Consolidated Balance Sheets | ||||||||||
| (unaudited, in thousands) | ||||||||||
| June 30, 2023 | December 31, 2022 | |||||||||
| Assets | ||||||||||
| Cash and cash equivalents | $ | 4,324 | $ | 4,508 | ||||||
| Accounts receivable, net | 16,903 | 16,705 | ||||||||
| Inventories | 26,089 | 26,439 | ||||||||
| Other current assets | 5,301 | 3,472 | ||||||||
| Total current assets | 52,617 | 51,124 | ||||||||
| Property, plant and equipment | 3,491 | 3,366 | ||||||||
| Goodwill and other intangibles | 75,127 | 77,274 | ||||||||
| Other long-term assets | 11,664 | 13,596 | ||||||||
| Total assets | $ | 142,899 | $ | 145,360 | ||||||
| Liabilities and Stockholders' Equity | ||||||||||
| Current portion, long-term debt | $ | 3,220 | $ | 3,811 | ||||||
| Other current liabilities | 19,722 | 19,438 | ||||||||
| Total current liabilities | 22,942 | 23,249 | ||||||||
| Long-term debt, net | 38,203 | 43,013 | ||||||||
| Other long-term liabilities | 6,366 | 6,878 | ||||||||
| Stockholders’ equity | 75,388 | 72,220 | ||||||||
| Total liabilities and stockholders’ equity | $ | 142,899 | $ | 145,360 | ||||||
| HARVARD BIOSCIENCE, INC. | ||||||||||||||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||||||||||||||
| (unaudited, in thousands) | ||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||
| June 30, 2023 | June 30, 2022 | June 30, 2023 | June 30, 2022 | |||||||||||||||||
| Cash flows from operating activities: | ||||||||||||||||||||
| Net (loss) income | $ | (980 | ) | $ | 2,435 | $ | (358 | ) | $ | (4,445 | ) | |||||||||
| Adjustments to operating cash flows | 4,615 | 4,302 | 7,101 | 7,120 | ||||||||||||||||
| Changes in operating assets and liabilities | (83 | ) | (6,927 | ) | (1,379 | ) | (4,851 | ) | ||||||||||||
| Net cash provided by (used in) operating activities | 3,552 | (190 | ) | 5,364 | (2,176 | ) | ||||||||||||||
| Cash flows from investing activities: | ||||||||||||||||||||
| Additions to property, plant and equipment | (517 | ) | (442 | ) | (741 | ) | (913 | ) | ||||||||||||
| Acquisition of intangible assets | (108 | ) | - | (108 | ) | - | ||||||||||||||
| Proceeds from sale of product line | - | - | 512 | - | ||||||||||||||||
| Net cash used in investing activities | (625 | ) | (442 | ) | (337 | ) | (913 | ) | ||||||||||||
| Cash flows from financing activities: | ||||||||||||||||||||
| Borrowing from revolving line of credit | 1,000 | 3,800 | 2,500 | 5,300 | ||||||||||||||||
| Repayment of revolving line of credit | (2,950 | ) | (3,600 | ) | (5,450 | ) | (3,600 | ) | ||||||||||||
| Repayment of term debt | (750 | ) | (750 | ) | (2,591 | ) | (1,686 | ) | ||||||||||||
| Proceeds from exercise of employee stock options and stock purchases | 620 | 251 | 724 | 282 | ||||||||||||||||
| Taxes paid related to net share settlement of equity awards | (295 | ) | (279 | ) | (451 | ) | (780 | ) | ||||||||||||
| Net cash used in financing activities | (2,375 | ) | (578 | ) | (5,268 | ) | (484 | ) | ||||||||||||
| Effect of exchange rate changes on cash | (17 | ) | 36 | 57 | 11 | |||||||||||||||
| Increase (decrease) in cash and cash equivalents | 535 | (1,174 | ) | (184 | ) | (3,562 | ) | |||||||||||||
| Cash and cash equivalents at the beginning of period | 3,789 | 5,433 | 4,508 | 7,821 | ||||||||||||||||
| Cash and cash equivalents at the end of period | $ | 4,324 | $ | 4,259 | $ | 4,324 | $ | 4,259 | ||||||||||||
| HARVARD BIOSCIENCE, INC. | ||||||||||||||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) | ||||||||||||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, 2023 | June 30, 2022 | June 30, 2023 | June 30, 2022 | |||||||||||||||||||||||
| GAAP operating income (loss) | $ | 796 | $ | 3,998 | $ | 2,545 | $ | (2,714 | ) | |||||||||||||||||
| Stock-based compensation | 1,102 | 1,239 | 2,255 | 2,262 | ||||||||||||||||||||||
| Acquired asset amortization | 1,398 | 1,488 | 2,798 | 2,992 | ||||||||||||||||||||||
| Restructuring & other | 276 | 1,212 | 408 | 2,573 | ||||||||||||||||||||||
| Settlement | - | (4,880 | ) | - | 311 | |||||||||||||||||||||
| Adjusted operating income | $ | 3,572 | $ | 3,057 | $ | 8,006 | $ | 5,424 | ||||||||||||||||||
| Operating margin | 2.8 | % | 13.7 | % | 4.3 | % | -4.7 | % | ||||||||||||||||||
| Adjusted operating margin | 12.4 | % | 10.5 | % | 13.6 | % | 9.4 | % | ||||||||||||||||||
| GAAP net (loss) income | $ | (980 | ) | $ | 2,435 | $ | (358 | ) | $ | (4,445 | ) | |||||||||||||||
| Stock-based compensation | 1,102 | 1,239 | 2,255 | 2,262 | ||||||||||||||||||||||
| Acquired asset amortization | 1,398 | 1,488 | 2,798 | 2,992 | ||||||||||||||||||||||
| Restructuring & other | 367 | 1,212 | 4 | 2,573 | ||||||||||||||||||||||
| Settlement | - | (4,880 | ) | - | 311 | |||||||||||||||||||||
| Unrealized loss on equity securities | 1,581 | - | 1,581 | - | ||||||||||||||||||||||
| Income taxes | (1,776 | ) | 517 | (2,115 | ) | (165 | ) | |||||||||||||||||||
| Adjusted net income | 1,692 | 2,011 | 4,165 | 3,528 | ||||||||||||||||||||||
| Depreciation | 328 | 340 | 649 | 683 | ||||||||||||||||||||||
| Interest and other expense, net | 1,222 | 576 | 2,258 | 882 | ||||||||||||||||||||||
| Adjusted income taxes (1) | 658 | 469 | 1,582 | 1,013 | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 3,900 | $ | 3,396 | $ | 8,654 | $ | 6,106 | ||||||||||||||||||
| Adjusted EBITDA margin | 13.6 | % | 11.6 | % | 14.7 | % | 10.5 | % | ||||||||||||||||||
| Diluted (loss) earnings per share (GAAP) | $ | (0.02 | ) | $ | 0.06 | $ | (0.01 | ) | $ | (0.11 | ) | |||||||||||||||
| Diluted adjusted earnings per share | $ | 0.04 | $ | 0.05 | $ | 0.09 | $ | 0.08 | ||||||||||||||||||
| Weighted-average common shares: | ||||||||||||||||||||||||||
| Diluted GAAP | 42,354 | 41,304 | 42,204 | 41,256 | ||||||||||||||||||||||
| Diluted Adjusted | 44,656 | 42,560 | 44,020 | 42,696 | ||||||||||||||||||||||
| June 30, 2023 | December 31, 2022 | June 30, 2022 | ||||||||||||||||||||||||
| Total debt | $ | 41,423 | $ | 46,824 | $ | 48,485 | ||||||||||||||||||||
| Unamortized deferred financing costs | 700 | 840 | 979 | |||||||||||||||||||||||
| Cash and cash equivalents | (4,324 | ) | (4,508 | ) | (4,259 | ) | ||||||||||||||||||||
| Net Debt | $ | 37,799 | $ | 43,156 | $ | 45,205 | ||||||||||||||||||||
| (1) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise. | ||||||||||||||||||||||||||
| Net leverage ratio is defined under our credit agreement as our net divided by our trailing twelve months adjusted EBITDA. | ||||||||||||||||||||||||||
| Last Trade: | US$2.14 |
| Daily Change: | -0.15 -6.55 |
| Daily Volume: | 334,673 |
| Market Cap: | US$93.330M |
November 07, 2024 October 03, 2024 September 18, 2024 June 06, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
